Business News

CHILDLY’s Dove Wallet Partners with Argos to Provide AML Solution

CHILDLY's Dove Wallet Partners with Argos to Provide AML Solution

CHILDLY announced that they have partnered with Argos, a global crypto KYC/AML solution provider, to build the automated compliance solution into the Dove Wallet and tighten its compliance standards as new regulatory demands come into place. Dove Wallet is CHILDLY’s crypto wallet service that introduces anti-money laundering (AML) and customer identification (KYC) solutions.

With the introduction of Argos KYC/AML solution, Dove Wallet expects to be able to comply with AML regulatory environments around the world more efficiently. It is also possible to prepare for the passage of an amendment to the Special Measure by the Korean government, which included the basis for implementation, along with last year’s FATF policy recommendation.

Read More: Hamilton Lane Implements Hazeltree Private Markets to Manage Capital Activity Lifecycle

“All aspects related to compliance and information protection is the utmost priority for Dove Wallet. We will continue to leverage the benefits of best compliance technologies available to provide a safe and legal crypto environment to our customers,” says Euntai Kim, CEO of CHILDLY.

In the meantime, Dove Wallet also said they are preparing to obtain ISO 27001 accreditation & ISMS (Information Security Management System) Certificate, the government-backed standard for the protection of key information assets, to satisfy increasing demand for higher standard of crypto security for the service.

Read More: Digital Receipt Solutions Provider TransactionTree Partners with Flooid to Provide Better Customer Journeys

Related posts

Patria Investments Announces Agreement to Acquire VBI Real Estate to Anchor Brazil Real Estate Platform

Fintech News Desk

DeFi Technologies Announces Inaugural Insights Symposium to Be Held in Frankfurt on September 25, 2025 English

PR Newswire

Legend Innovation Life Science Fund Announces Investment Commitment of Up to $50 Million in Mid-Atlantic BioTherapeutics, Inc.

Cision PRWeb
1